Pharmaceuticals

Pulmonary Or Respiratory Drug Delivery Market Growth Projection: Expected to Surpass $114.23 Billion by 2030 at 8.6% CAGR

February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the pulmonary or respiratory drug delivery market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Pulmonary Or Respiratory Drug Delivery Market show for the 2026–2030 period?

The pulmonary or respiratory drug delivery market has demonstrated substantial growth in recent years. This market is anticipated to expand from $75.67 billion in 2025 to $82.23 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.7%. Historical market expansion can be credited to factors including the increasing prevalence of asthma and copd, extensive adoption of inhalers, an increase in the number of respiratory hospitals, enhancements in aerosol technologies, and the broadening availability of homecare treatments.

The pulmonary or respiratory drug delivery market is projected to experience significant growth in the coming years, reaching $114.23 billion by 2030 at a compound annual growth rate (CAGR) of 8.6%. The expansion during the forecast period is attributable to elements such as an aging population, increased exposure to air pollution, the advancement of digital inhalers, the broadening of homecare settings, and a rise in chronic respiratory conditions. Prominent trends expected in this period involve the increasing adoption of inhalation-based drug delivery, a growing demand for home-based respiratory therapies, more widespread use of dry powder and metered dose inhalers, the expansion of chronic respiratory disease management, and an enhanced focus on patient-friendly delivery devices.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp

What Drivers Are Shaping The Development Of The Pulmonary Or Respiratory Drug Delivery Market?

The anticipated expansion of the pulmonary or respiratory drug delivery market is primarily driven by the rising incidence of pneumonia. Pneumonia, a pulmonary infection, triggers inflammation in the air sacs, potentially leading to a buildup of fluid or pus, and manifesting symptoms such as coughing, fever, and impaired breathing. This increase in pneumonia cases is linked to factors like an aging demographic, compromised immune systems, other respiratory infections, environmental air pollution, tobacco use, and the emergence of antibiotic-resistant bacteria. The pulmonary or respiratory drug delivery method offers benefits to pneumonia patients by administering medications, including antibiotics, bronchodilators, or anti-inflammatory agents, directly to the lungs. This approach facilitates quicker and more potent treatment, effectively mitigating symptoms, reducing inflammation, eradicating infections, and enhancing lung function, thereby promoting recovery and averting complications. As an illustration, data from December 2024, sourced from Clinical Trials Arena, a UK-based clinical research news platform, indicated a significant surge in hospital admissions for Mycoplasma pneumoniae. These admissions saw a 461% rise between October 2023 and February 2024, escalating from 110 to 617 admissions. Among the reported pneumonia cases, 20.2% were identified in children aged 0 to 4 years, 25.4% in those aged 5 to 9 years, and 17.5% in the 10 to 14 years age group, accounting for 410 out of 650 total reported cases. Consequently, the expanding occurrence of pneumonia is a key factor propelling the pulmonary or respiratory drug delivery market.

Which Segments Are Contributing To The Growth Of The Pulmonary Or Respiratory Drug Delivery Market?

The pulmonary or respiratory drug delivery market covered in this report is segmented –

1) By Product: Formulation Type, Device Type

2) By Canister Type: Plain Canister, Coated Canister

3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications

4) By End-User: Hospitals, Clinics, Home Care Settings

Subsegments:

1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays

2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices

What Trends Are Reshaping The Dynamics Of The Pulmonary Or Respiratory Drug Delivery Market?

Leading companies in the pulmonary or respiratory drug delivery market are focusing on advancements in technology, particularly complex drug delivery systems, to improve treatment effectiveness and patient compliance. These intricate drug delivery systems are sophisticated technologies that optimize the targeted administration and controlled release of therapeutic agents, consequently enhancing drug efficacy and patient outcomes. For example, in July 2023, Viatris Inc., a US-based healthcare company known for manufacturing generic and branded medicines, along with Kindeva Drug Delivery L.P., a US-based company providing drug delivery solutions, launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. This inhalation aerosol, approved by the Food and Drug Administration, a US-based government agency, represents the first generic version of AstraZeneca’s Symbicort. It is a metered-dose inhaler that combines budesonide and formoterol, indicated for treating asthma and chronic obstructive pulmonary disease, and is available in two strengths: 80 micrograms and 160 micrograms, both containing 4.5 micrograms of formoterol.

Who Are The Major Companies Operating In The Pulmonary Or Respiratory Drug Delivery Market?

Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pulmonary-or-respiratory-drug-delivery-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Pulmonary Or Respiratory Drug Delivery Market?

North America was the largest region in the pulmonary or respiratory drug delivery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pulmonary Or Respiratory Drug Delivery Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20939&type=smp

Browse Through More Reports Similar to the Global Pulmonary Or Respiratory Drug Delivery Market 2026, By The Business Research Company

Pulmonary Drug Delivery Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/pulmonary-drug-delivery-devices-global-market-report

Pharmaceutical Drug Delivery Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report

Respiratory Disease Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795